[xoo_el_inline_form active="login"]
賽昂生醫的T細胞「裝甲」介紹：雙功能抗體 (BsAb)
賽昂生醫開發了一系列獨特的雙功能抗體 (BsAb)，作為T細胞的導航系統，用於靶向並摧毀癌細胞。BsAb 的雙臂結構使其能同時作用於兩個目標：其中一隻手與 T 細胞上的 T 細胞受體（通常是 CD3）結合，活化 T 細胞；而另一隻手則與癌細胞表面的特定抗原結合。這種精確的標靶機制可以有效引導 T 細胞滲入癌細胞，直接促進T細胞毒殺效果並摧毀腫瘤。
賽昂生醫 BsAb 的主要機轉
賽昂的雙功能抗體 (BsAb) 通過以下四個步驟，同時活化T細胞毒殺功能，且標靶癌細胞上的腫瘤特異性抗原，引導已活化的 T 細胞進行專一性攻擊，誘導癌細胞凋亡
武裝T細胞
One arm of the BsAb binds to CD3 receptors on T cells, activating their cytotoxic potential.
標靶腫瘤抗原
The other arm binds to tumor-specific antigens on cancer cells.
活化T細胞
This binding activates the T cells and directs them to attack the cancer cells
專一破壞腫瘤
T cells release cytotoxic granules that induce apoptosis (programmed cell death) in the cancer cells
CytoArm’s BsAb:
Limitless Potential for Drug Development
CytoArm holds comprehensive patents for its bi-specific antibody “armour” platform.
By modifying the tumor-targeting components of our BsAb, we can develop nearly limitless antibody therapies.
Our BsAb platform targets a wide range of common and novel cancer markers.
Collaborative Opportunities with CytoArm’s BsAb:
Co-development of Specific Armed-T Cells:
Partner with CytoArm to create custom BsAb therapies for specific cancers.
Partner with CytoArm to create custom BsAb therapies for specific cancers.
Optimize Existing T-cell Therapies:
Enhance your current cell therapy platforms with the precision and efficacy of CytoArm’s BsAb technology.
Enhance your current cell therapy platforms with the precision and efficacy of CytoArm’s BsAb technology.
Chinese 
English